Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials-Reference-Cited by-同舟云学术

Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials

Published:2020-05 Issue:5 Volume:27 Page:497-504
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Poordad Fred¹,Castro RuiSarmento E.²,Asatryan Armen³,Aguilar Humberto⁴,Cacoub Patrice⁵⁶,Dieterich Douglas⁷,Marinho Rui Tato⁸,Carvalho Armando⁹,Siddique Asma¹⁰,Hu Yiran Bonnie³,Charafeddine Mariem³,Bondin Mark³,Khan Nader³,Cohen Daniel E.³,Felizarta Franco¹¹

Affiliation:

1. The Texas Liver InstituteUniversity of Texas Health San Antonio TX USA

2. Hospital Centre of Porto (Portugal) Biomedical School of Medicine (University of Porto) Porto Portugal

3. AbbVie Inc. North Chicago IL USA

4. Louisiana Research Center Shreveport LA USA

5. Department of Internal Medicine and Clinical Immunology AP HP Groupe hospitalier La Pitié‐Salpêtrière Paris France

6. Sorbonne Universités UPMC Univ Paris France

7. Mount Sinai School of Medicine Icahn School of Medicine at Mount Sinai New York NY USA

8. Gastroenterology and Hepatology Department Centro Hospitalar de Universitário Lisboa Norte and Medical School of Lisbon University of Lisbon Lisbon Portugal

9. Internal Medicine Department Hospitais da Universidade de Coimbra (Centro Hospitalar e Universitário de Coimbra) Coimbra Portugal

10. Virginia Mason Hospital and Seattle Medical Center Seattle WA USA

11. Private Practice Bakersfield CA USA

Funder

AbbVie

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13261

Reference37 articles.